SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Geron Corp.
GERN 1.345+2.7%Jan 14 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Bottom_Dweller who wrote (365)8/18/1997 3:16:00 PM
From: sds   of 3578
 
Not quite....

First let me say that I've agreed with almost everything you've said to this point. You're comment about writing in Science was a little inaccurate, though. Co.'s routinely publish their research results in scientific journals long before a drug formula is ready (remember Amgen's skinny leptin-mice?). The company has a patent on the gene and the associated RNA and so has nothing to lose by going public with it discovery. Going public gives the company much-needed attention (and capital) and allows management to make something of their stock options.

So, while you are certainly right that commercialization is a tiny blip on the horizon, I don't think you can say that their technology has no commercial value simply because they published their results in such a highly respected journal as Science

sds
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News